Location · Flowood, MS
Clinical trials in Flowood, MS
32 recruiting studies have a site in Flowood, and 0 of them accept healthy volunteers.
32 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Flowood, MS + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Flowood, MS + 112 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With…
LivaNova
- Location
- Flowood, MS + 49 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bristol-Myers Squibb
- Location
- Flowood, MS + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
AbbVie
- Location
- Flowood, MS + 60 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Flowood, MS + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Flowood, MS + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals
- Location
- Flowood, MS + 16 other US sites
- Eligibility basics
- Ages 12–100
- RecruitingPhase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sanofi
- Location
- Flowood, MS + 20 other US sites
- Eligibility basics
- Ages 10–65
- RecruitingPhase 2
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
MapLight Therapeutics
- Location
- Flowood, MS + 41 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
- Location
- Flowood, MS + 130 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Alto Neuroscience
- Location
- Flowood, MS + 38 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals
- Location
- Flowood, MS + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
- Location
- Flowood, MS + 136 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Flowood, MS + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Draig Therapeutics Ltd
- Location
- Flowood, MS + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Flowood, MS + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Flowood, MS + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Centessa Pharmaceuticals (UK) Limited
- Location
- Flowood, MS + 19 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Flowood, MS + 58 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 3
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Agios Pharmaceuticals, Inc.
- Location
- Flowood, MS + 2 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Flowood, MS + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Flowood, MS + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Flowood, MS + 18 other US sites
- Eligibility basics
- Ages 18–65